Editas Medicine EDIT Stock
Editas Medicine Price Chart
Editas Medicine EDIT Financial and Trading Overview
| Editas Medicine stock price | 2.76 USD |
| Previous Close | 2.69 USD |
| Open | 2.69 USD |
| Bid | 2.04 USD x 200 |
| Ask | 3.45 USD x 200 |
| Day's Range | 2.69 - 2.88 USD |
| 52 Week Range | 1.66 - 4.54 USD |
| Volume | 2.88M USD |
| Avg. Volume | 2.15M USD |
| Market Cap | 429.69M USD |
| Beta (5Y Monthly) | 2.1 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.78 USD |
EDIT Valuation Measures
| Enterprise Value | 167.79M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9900155 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 11.105191 |
| Price/Book (mrq) | 62.222218 |
| Enterprise Value/Revenue | 4.336 |
| Enterprise Value/EBITDA | -1.97 |
Trading Information
Editas Medicine Stock Price History
| Beta (5Y Monthly) | 2.1 |
| 52-Week Change | 24.44% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 4.54 USD |
| 52 Week Low | 1.66 USD |
| 50-Day Moving Average | 2.94 USD |
| 200-Day Moving Average | 2.67 USD |
EDIT Share Statistics
| Avg. Volume (3 month) | 2.15M USD |
| Avg. Daily Volume (10-Days) | 2.31M USD |
| Shares Outstanding | 153.46M |
| Float | 79.28M |
| Short Ratio | 5.96 |
| % Held by Insiders | 0.17% |
| % Held by Institutions | 49.25% |
| Shares Short | 15.07M |
| Short % of Float | 9.83% |
| Short % of Shares Outstanding | 9.81% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -281.58% |
| Operating Margin (ttm) | -883.18% |
| Gross Margin | -109.23% |
| EBITDA Margin | -220.15% |
Management Effectiveness
| Return on Assets (ttm) | -26.94% |
| Return on Equity (ttm) | -326.073% |
Income Statement
| Revenue (ttm) | 38.69M USD |
| Revenue Per Share (ttm) | 0.42 USD |
| Quarterly Revenue Growth (yoy) | -39.20% |
| Gross Profit (ttm) | -42267000 USD |
| EBITDA | -85186000 USD |
| Net Income Avi to Common (ttm) | -108954000 USD |
| Diluted EPS (ttm) | -1.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 123.65M USD |
| Total Cash Per Share (mrq) | 1.26 USD |
| Total Debt (mrq) | 17.3M USD |
| Total Debt/Equity (mrq) | 392.4 USD |
| Current Ratio (mrq) | 3.219 |
| Book Value Per Share (mrq) | 0.045 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -140503008 USD |
| Levered Free Cash Flow (ttm) | -73816000 USD |
Profile of Editas Medicine
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 11 Hurley Street |
| ZIP | 02141 |
| Phone | 617 401 9000 |
| Website | https://www.editasmedicine.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 87 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Q&A For Editas Medicine Stock
What is a current EDIT stock price?
Editas Medicine EDIT stock price today per share is 2.76 USD.
How to purchase Editas Medicine stock?
You can buy EDIT shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Editas Medicine?
The stock symbol or ticker of Editas Medicine is EDIT.
Which industry does the Editas Medicine company belong to?
The Editas Medicine industry is Biotechnology.
How many shares does Editas Medicine have in circulation?
The max supply of Editas Medicine shares is 153.46M.
What is Editas Medicine Price to Earnings Ratio (PE Ratio)?
Editas Medicine PE Ratio is now.
What was Editas Medicine earnings per share over the trailing 12 months (TTM)?
Editas Medicine EPS is -1.14 USD over the trailing 12 months.
Which sector does the Editas Medicine company belong to?
The Editas Medicine sector is Healthcare.
Editas Medicine EDIT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
- {{ link.label }} {{link}}